Vaxxel develops novel and proprietary live-attenuated vaccines candidate against bronchiolitis and pneumonia and in particular against human Metnapneumovirus and against human Respiratory Virus. Vaxxel is a spin off fom Virpath, the virology and human pathology Laboratory of the University Claude Bernard in Lyon (UCBL), France, and has been founded by Dr. Manuel Rosa-Calatrava Co-Director of Virpath (Lyon), Pr. Guy Boivin of the University of Laval (Quebec), by Denis Cavert, President of Vaxxel.
Location: France, Auvergne-Rhône-Alpes, Villeurbanne
Employees: 1-10
Total raised: $1.3M
Founded date: 2019
Investors 1
| Date | Name | Website |
| - | Femmes Bus... | femmesbusi... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.03.2022 | Seed | $1.3M | - |
Persons 1
| Date | First Name | Last Name | Title | |||
| - | Denis | Cavert | Chief Exec... | linkedin.c... | - | d*********... |